In-vivo-quantification of both serotonin-and norepinephrin-transporter availability in obese persons without co-morbid depression using positron emission tomography (PET) and selective radio-labelled markers - comparison with healthy controls and 6 months after a multimodal treatment program

In-vivo-quantification of both serotonin-and norepinephrin-transporter availability in obese persons without co-morbid depression using positron emission tomography (PET) and selective radio-labelled markers - comparison with healthy controls and 6 months after a multimodal treatment program - IFB-PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00003537

Enrollment

Registered

2012-05-30

Start date

2011-12-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eating behaviour, eating disorders E66

Interventions

Group 1: obese persons BMI >35 undergoing DASB-PET before and after 6 month of participation in a multimodal treatment program including physical exercise, nutrition information and motivational thera

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: • Age between 18 and 65 • BMI > 35 kg/m2 resp. <30 kg/m2 • no psychotropic-medication and/or drugs for at least 8 weeks prior PET • written informed consent

Exclusion criteria

Exclusion criteria: • History of neurological or psychiatric diseases • juvenile-onset diabetes (type 1) resp. insulin dependent diabetes type 2, malignant hypertension • medical treatment or surgery for weight reduction less then 6 months ago • Structural lesions (stroke, traumatic brain injury etc.) • Cognitive deficits, major speech impairment, alcohol- or drug abuse (positive drug test) • Major mental disorders, major communicative deficiencies which inhibit an informed consent • neurosurgical interventions in the past • Epilepsy, cerebral seizures in previous medical history (or in history of the family) • Chronic diseases (e.g. asthma) indicating chronic medical treatment with central effect • Pregnancy (exclusion via urine test before the experiment) • Contraindications for MR imaging (e.g., implanted ferro-magnetic devices), claustrophobia

Design outcomes

Primary

Measure	Time frame
quantified central SERT /NET availability (binding-potential BP and distribution volume [ratios] DV[R]) in obese patients (BMI = 35 kg/m2) before compared to after participation in a multimodal treatment program in order to compare BP/DV[R] between the two groups (obese, obese after paricipation of treatment program and normal weighted).	—

Secondary

Measure	Time frame
Correlation coefficients with other parameters like genotype, stress reaction, age, gender. Comparison of the obese subjects before and after 6 month of participation in the treatment program with the nomalweighted subjects.	—

Countries

Germany

Contacts

Public ContactFranziska Zientek

Univesitätsklinikum Leipzig AöR Klinik und Poliklinik für Nuklearmedizin

franziska.zientek@medizin.uni-leipzig.de+49 341/ 97 18048

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026